BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
$R$LOCK|D?JG!LOCK|F%@Zww

BioMérieux Earnings: Strong First-Quarter 2025 Results and Confirmation on Full-Year Guidance

BioMérieux reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales increased in constant currency by 12.7%. Shares are trading 6% lower intraday on April 17.

Sponsor Center